TLP
Tri Locum Partners Portfolio holdings
AUM
$330M
This Quarter Return
+9.29%
1 Year Return
+35.44%
3 Year Return
+388.28%
5 Year Return
–
10 Year Return
–
AUM
$314M
AUM Growth
+$314M
(+14%)
Cap. Flow
+$28.3M
Cap. Flow
% of AUM
9.02%
Top 10 Holdings %
Top 10 Hldgs %
74.73%
Holding
80
New
15
Increased
11
Reduced
3
Closed
50
Top Buys
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$27M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$25.7M |
| 3 |
Bristol-Myers Squibb
BMY
|
$24.4M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$18.1M |
| 5 |
Humana
HUM
|
$15M |
Top Sells
| 1 |
AbbVie
ABBV
|
$20.7M |
| 2 |
Viatris
VTRS
|
$19.6M |
| 3 |
Labcorp
LH
|
$11M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$10.3M |
| 5 |
Zai Lab
ZLAB
|
$8.42M |
Sector Composition
| 1 | Healthcare | 92.99% |
| 2 | Technology | 4.64% |
| 3 | Communication Services | 0% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Regeneron Pharmaceuticals
REGN
$61.5B
| $30.6M | 7.59% | 64,705 +54,282 | +521% | +$25.7M |
|
2
Medtronic
MDT
$119B
| $28.3M | 7.02% | 239,644 +35,506 | +17% | +$4.19M |
|
3
Johnson & Johnson
JNJ
$427B
| $27.7M | 6.87% | 168,634 +6,001 | +4% | +$986K |
|
|
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $27M | 6.7% | +293,426 | New | +$27M |
|
5
Baxter International
BAX
$12.7B
| $26.5M | 6.57% | 314,136 +15,415 | +5% | +$1.3M |
|
|
6
Bristol-Myers Squibb
BMY
$96B
| $24.7M | 6.12% | 390,992 +386,795 | +9,216% | +$24.4M |
|
|
WBA
7
DELISTED
Walgreens Boots Alliance
WBA
| $22M | 5.44% | 399,842 -41,482 | -9% | -$2.28M |
|
|
8
Jazz Pharmaceuticals
JAZZ
$7.75B
| $18.1M | 4.5% | +110,382 | New | +$18.1M |
|
|
9
Humana
HUM
$36.5B
| $15M | 3.71% | +35,693 | New | +$15M |
|
|
NUAN
10
DELISTED
Nuance Communications, Inc.
NUAN
| $14.6M | 3.61% | +333,482 | New | +$14.6M |
|
11
Eli Lilly
LLY
$657B
| $9.02M | 2.24% | 48,299 -7,222 | -13% | -$1.35M |
|
|
NMTR
12
DELISTED
9 Meters Biopharma, Inc. Common Stock
NMTR
| $7.77M | 1.93% | 6,644,337 +5,253,516 | +378% | +$6.15M |
|
13
TG Therapeutics
TGTX
$4.65B
| $7.16M | 1.78% | 148,620 +78,688 | +113% | +$3.79M |
|
14
Protagonist Therapeutics
PTGX
$3.67B
| $6.66M | 1.65% | 257,086 -2,197 | -0.8% | -$56.9K |
|
|
MYOV
15
DELISTED
Myovant Sciences Ltd.
MYOV
| $6.61M | 1.64% | 321,101 +280,191 | +685% | +$5.77M |
|
|
TRIL
16
DELISTED
Trillium Therapeutics Inc.
TRIL
| $6.22M | 1.54% | 578,930 +282,092 | +95% | +$3.03M |
|
17
Aclaris Therapeutics
ACRS
$209M
| $4.14M | 1.03% | +164,199 | New | +$4.14M |
|
18
Celldex Therapeutics
CLDX
$1.47B
| $4.05M | 1% | +196,672 | New | +$4.05M |
|
19
Syndax Pharmaceuticals
SNDX
$1.41B
| $4.03M | 1% | 180,261 +61,428 | +52% | +$1.37M |
|
|
INFI
20
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $3.91M | 0.97% | +1,210,863 | New | +$3.91M |
|
21
CASI Pharmaceuticals
CASI
$35.8M
| $3.6M | 0.89% | +1,500,000 | New | +$3.6M |
|
22
Black Diamond Therapeutics
BDTX
$157M
| $3.47M | 0.86% | 142,911 +132,628 | +1,290% | +$3.22M |
|
|
SNCE
23
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $3.04M | 0.75% | 300,000 | – | – |
|
24
Cyclacel Pharmaceuticals
CYCC
$18.4M
| $2.09M | 0.52% | +293,419 | New | +$2.09M |
|
|
BLU
25
DELISTED
BELLUS Health Inc.
BLU
| $1.46M | 0.36% | +380,237 | New | +$1.46M |
|